Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
RACE US​

Ferrari N.V.(RACE US)

$393.28-4.381.10%Ext:$395.29+2.010.51%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Ferrari N.V. — Company Profile

Ferrari N.V. is a renowned automotive manufacturer primarily engaged in the creation, engineering, production, and sale of an exclusive range of high-performance luxury automobiles. Its extensive vehicle lineup features diverse models, including traditional sports cars, Grand Tourers (GTs), specialized series editions, ultra-exclusive limited-edition hypercars, bespoke one-off vehicles, track-specific designs, and its distinctive Icona series. Beyond car manufacturing, the company also supplies motorsport vehicles, essential components like spare parts and engines, and delivers comprehensive after-sales services such as vehicle repair, maintenance, and restoration. Expanding its brand influence, Ferrari N.V. strategically licenses its iconic marque to various producers and retailers of upscale lifestyle merchandise. This also extends to prominent leisure destinations, including the Ferrari World theme park in Abu Dhabi, UAE, and Ferrari Land Portaventura in Europe. The company further diversifies its operations by offering direct and indirect financing and leasing solutions to both individual customers and dealership partners. Additionally, Ferrari N.V. oversees the management of racetracks, curates and maintains two dedicated museums in Maranello and Modena, Italy, and markets its own collection of branded apparel and accessories through specialized monobrand boutiques. As of December 31, 2021, Ferrari's global retail presence comprised 30 branded stores, with 14 operating as franchised outlets and 16 as company-owned locations. Its products are also distributed globally through a network of 172 authorized dealers, collectively operating 191 sales points, and are available for purchase directly via its official e-commerce platform, store.ferrari.com. Established in 1947, Ferrari N.V. maintains its headquarters in Maranello, Italy.

Sector
Consumer Discretionary
Industry
Automobiles
Exchange
UN
CEO
Benedetto Vigna
Headquarters
Maranello, L6, IT
IPO Date
Oct 21, 2015
Employees
5,743
Website
www.ferrari.com

Key Metrics

Price
$388.33
Market Cap
$68.31B
Revenue (TTM)
$1.85B
Net Income (TTM)
$412.86M
EPS (TTM)
2.35
P/E (TTM)
42.75
P/B (TTM)
16.81
Dividend Yield
118.50%
ROE (TTM)
10.16%
ROA (TTM)
4.02%
Operating Margin
29.88%
Beta
0.77

Dividends

Last Dividend
$4.25
Last Yield
1.18%

Summary

Ferrari N.V. is a renowned automotive manufacturer primarily engaged in the creation, engineering, production, and sale of an exclusive range of high-performance luxury automobiles. Its extensive vehicle lineup features diverse models, including traditional sports cars, Grand Tourers (GTs), specialized series editions, ultra-exclusive limited-edition hypercars, bespoke one-off vehicles, track-specific designs, and its distinctive Icona series. Beyond car manufacturing, the company also supplies motorsport vehicles, essential components like spare parts and engines, and delivers comprehensive after-sales services such as vehicle repair, maintenance, and restoration. Expanding its brand influence, Ferrari N.V. strategically licenses its iconic marque to various producers and retailers of upscale lifestyle merchandise. This also extends to prominent leisure destinations, including the Ferrari World theme park in Abu Dhabi, UAE, and Ferrari Land Portaventura in Europe. The company further diversifies its operations by offering direct and indirect financing and leasing solutions to both individual customers and dealership partners. Additionally, Ferrari N.V. oversees the management of racetracks, curates and maintains two dedicated museums in Maranello and Modena, Italy, and markets its own collection of branded apparel and accessories through specialized monobrand boutiques. As of December 31, 2021, Ferrari's global retail presence comprised 30 branded stores, with 14 operating as franchised outlets and 16 as company-owned locations. Its products are also distributed globally through a network of 172 authorized dealers, collectively operating 191 sales points, and are available for purchase directly via its official e-commerce platform, store.ferrari.com. Established in 1947, Ferrari N.V. maintains its headquarters in Maranello, Italy.

Website
www.ferrari.com
Location
Maranello, L6, IT
Phone39 0536 94 91 11
Employees5,743
CEOBenedetto Vigna
Sector
Consumer Discretionary
Industry
Automobiles
IPO DateOct 21, 2015

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(633)

Expand
  • 6-KCurrent report (foreign private issuer)19 Oct
  • 6-KCurrent report (foreign private issuer)16 Oct
  • 6-KCurrent report (foreign private issuer)13 Oct
  • 6-KCurrent report (foreign private issuer)5 Oct
  • 6-KCurrent report (foreign private issuer)28 Sep
  • 6-KCurrent report (foreign private issuer)21 Sep
  • 6-KCurrent report (foreign private issuer)17 Sep
  • 6-KCurrent report (foreign private issuer)14 Sep
  • 6-KCurrent report (foreign private issuer)8 Sep
  • 6-KCurrent report (foreign private issuer)1 Sep
  • 6-KCurrent report (foreign private issuer)31 Jul
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 6-KCurrent report (foreign private issuer)30 Jul
  • 6-KCurrent report (foreign private issuer)27 Jul
  • 6-KCurrent report (foreign private issuer)20 Jul
  • 6-KCurrent report (foreign private issuer)15 Jul
  • 6-KCurrent report (foreign private issuer)13 Jul
  • 6-KCurrent report (foreign private issuer)6 Jul
  • 6-KCurrent report (foreign private issuer)29 Jun
  • 6-KCurrent report (foreign private issuer)23 Jun

News

  • Ferrari CEO hails Tesla Roadster redesign as the bold innovation the industry needs20 Oct
  • FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM19 Oct
  • Ferrari N.V. $RACE Shares Bought by Banque Pictet & Cie SA17 Oct
  • FERRARI TO ANNOUNCE THIRD QUARTER 2026 FINANCIAL RESULTS ON NOVEMBER 316 Oct
  • Ferrari chair: I'm not an AI bubble believer12 Oct
  • Top 50 High-Quality Dividend Growth Stocks For October 202611 Oct
  • Ferrari's chairman is bullish on AI. He's less certain how businesses will cash in9 Oct
  • Bezos quip, Ive design shaped Ferrari's Luce EV, Elkann says7 Oct
  • Ferrari gets UBS backing as dealer survey points to resilient demand5 Oct
  • FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM5 Oct
  • MGA or RACE: Which Is the Better Value Stock Right Now?30 Sep
  • $1,000 Invested in Ferrari at Its 2026 Low Is Worth This Much Today30 Sep
  • FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM28 Sep
  • Prediction: Ferrari Is a Better Buy Than Ford for the Next Decade26 Sep
  • The Elite Portfolio: Why Savvy Investors Are Backing These Overlooked Stocks23 Sep
  • FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM21 Sep
  • The Under-the-Radar Stock Big Money Is Quietly Buying Up17 Sep
  • NewEdge Advisors LLC Buys 1,331 Shares of Ferrari N.V. $RACE17 Sep
  • FERRARI TO PARTNER WITH RAKUTEN17 Sep
  • THRM vs. RACE: Which Stock Should Value Investors Buy Now?14 Sep

Mentions in Filings

  • … nd development partnership with New Horizon Health Limited, Grand Cayman, Cayman Islands. The partnership builds on complimentary platform and biomarker developments with utility in cancer patient management. In 2022, <strong>Immunovia AB</strong> (Sweden) (“Immunovia”) partnered with Proteomedix to leverage Proteomedix’s research and development capabilities and advances their research and development efforts. With this partnership, Immunovia gained a more fle …
    Onconetix, Inc.Ferrari N.V.·ARS - Annual report to security holders·FY25·16 Oct
  • … l Officer and Treasurer of Myriad Genetics, Inc. Mr. Riggsbee currently serves as an independent director of CareDx, Inc. (since 2024), where he chairs the Audit and Finance Committee, and as an independent director of <strong>Immunovia AB</strong> (since 2025), where he serves on the Audit and Remuneration Committees. Earlier in his career, Mr. Riggsbee held finance leadership roles with Laboratory Corporation of America, GE, and KPMG. Jennifer Evans Stacey, ag …
    NEOGEN CORPFerrari N.V.·DEF 14A - Definitive proxy statement·Q1 27·21 Aug
  • … ther revenue including license revenue through agreements that grant third parties rights to use its intellectual property and proprietary materials. In September 2025, the Company entered into a license agreement with <strong>Immunovia AB</strong>, under which it granted exclusive rights to certain intellectual property and transferred biological materials related to the PancreaSure™ test. The agreement included two non-refundable payments of $0.3 million. Based …
    Onconetix, Inc.Ferrari N.V.·10-Q - QUARTERLY REPORT Q1·Q1 26·13 May
  • … eld, including Aqtual, Inc. Other potential competitors include companies that might develop diagnostic or disease or drug monitoring products, such as AMPEL BioSolutions, LLC; DxTerity Diagnostics Inc.; Genalyte Inc.; <strong>Immunovia AB</strong>; Oncimmune Holdings plc; and Progentec Diagnostics Inc. In the future, we may also face competition from companies developing new products or technologies. We believe the principal competitive factors in our target mar …
    EXAGEN INC.Ferrari N.V.·ARS - Annual report to security holders·FY25·27 Apr
  • … | | | | | | | --- | --- | --- | --- | --- | | 10.12 | Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company. | 10-Q | 10.14 | October 20, 2023 | | 10.13†# | Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC. | 10-Q | 10.6 | November 17, 2023 | | 10.14 | Form of Lock-Up Agreement …
    Onconetix, Inc.Ferrari N.V.·S-1/A - AMENDMENT NO. 1 TO FORM S-1·Q3 26·31 Aug
  • … consisted of the following as of June 30, 2026 and December 31, 2025: | | | | | | | --- | --- | --- | --- | --- | | | June 30, 2026 | | December 31, 2025 | | | Accrued compensation | $ | 14,884 | $ | 42,228 | | Accrued professional fees | | 138,093 | | 201,208 | | Other accrued expenses | | 16,630 | | 18,445 | | Accrued franchise taxes | | 80,000 | | 80,000 | | Total | $ | 249,607 | $ | 341,881 | Note 5 — Significant Agreements *<strong>Immunovia AB</strong>* …
    Onconetix, Inc.Ferrari N.V.·10-Q - QUARTERLY REPORT Q2·Q2 26·13 Aug

Key Stats

Trading

Px/Chg 1D$388.33 / +0.27%
Avg Volume639.80K
Beta0.77
Mkt Cap68.31B
FD Mkt Cap74.50B

Float

Shrs Out/Float175.92M / 124.04M
Short Float0.03%
Days to Cover6.20
Stock Repurchased$226.66M

Current Valuation

EV69.39B
EV/EBITDA25.75
EV/Sales9.63
P/B16.81
P/S9.48
FCF Yield1.07%
ROE10.16%
ROA4.02%
Current Ratio2.41

Dividend

Cash$4.25
Yield118.50%
Yield (TTM)118.50%

Estimates

P/E42.75
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings98.2852.7263.1050.75159.39165.46
Price / Sales21.009.6513.2311.5733.6036.96
Price / Book Value19.7918.9625.8121.8615.4916.81
Price / Free Cash Flow78.8282.1293.1982.3943.0493.37
ENTERPRISE VALUE METRICS
Enterprise Value68,231.750,597.180,366.078,856.361,944.069,394.9
Enterprise Value / Sales21.439.9313.4611.8134.3937.55
Enterprise Value / EBITDA55.9228.5535.0230.4089.3196.30
Enterprise Value / EBIT76.1241.2849.2340.91122.27126.90

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue13.7%4,270.95,095.35,970.16,676.77,145.8
Gross Income13.9%2,190.32,446.32,974.33,347.23,692.8
EBITDA16%1,529.71,772.02,294.62,594.32,766.7
EBIT18.3%1,073.71,225.81,632.31,927.52,104.8
Net Income17.7%830.8932.61,252.01,521.91,596.9
EPS (Diluted)18.8%4.505.096.908.468.96
BALANCE SHEET
Cash & ST Inv2.3%1,346.11,396.01,127.51,747.91,472.1
Total Assets8.8%6,863.57,765.88,051.39,497.19,628.4
Total Liabilities5.3%4,652.15,163.34,980.75,953.95,713.6
Total Shareholder Equity15.4%2,205.92,592.93,060.93,533.93,906.9
CASH FLOW
Net Operating Cash Flow34.4%1,282.71,403.31,716.61,926.74,179.5
Cap Ex19.9%-737.1-804.6-868.9-989.2-1,521.7
Free Cash Flow48.6%545.6598.7847.7937.52,657.8

Enterprise Value Bridge

Millions EUR23 Oct '26
Price (As of 23 Oct '26)393.11
Basic Shares175.92
Market Cap69,154.4
Diluted Shares177.32
Fully Diluted Shares Outstanding177.32
Fully Diluted Market Cap69,706.3
+Consolidated Debt2,940.1
−In-the-Money Convertible Debt—
+Capital Leases130.6
+Operating Leases—
−Cash & Equivalents-1,864.4
−Short-term Investments-34.8
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest5.8
+Pension Liabilities—
Enterprise Value70,235.8

Segment data

Revenue

by Products and services

  • Cars And Spare Parts84%
  • Sponsorship, Commercial And Brand11%
  • Other Revenues4%

Revenue

by Geography

  • Emea Excluding Italy30%
  • Americas22%
  • United States20%
  • Apac Excluding China9%
  • Germany6%

Related companies

Toyota Motor Corp/

TM US

Byd Co Ltd

BYDDF US

General Motors Co

GM US

Paccar Inc

PCAR US

Honda Motor Co Ltd

HMC US

Volkswagen AG

VLKPF US

Kia Corporation

000270 KP

SAIC Motor Corporation Limited

600104 CG

Rivian Automotive, Inc. / DE

RIVN US

Tata Motors Ltd/fi

TMCV IS

Sinotruk (Hong Kong) Ltd

SHKLY US

Stellantis N.V.

STLA US